A US-based KOL assesses trends in the endometrial cancer landscape with an analysis of current and future treatment and diagnosis guidelines. This interview also covers the unmet needs within the indication as well as a clinical trial overview of some of the most promising medicines in the development pipeline.

This interview was conducted on 12 November 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.